MktsMarkets

Relmada Therapeutics, Inc.
NASDAQ: RLMDKey statistics
RLMD News
Stories mentioning RLMD from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 8,088 | 8,073 | 4,036 | 2,819 | 11,951 | 11,001 | 11,149 | 10,721 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 19,462 | 20,334 | 10,327 | 10,221 | 18,218 | 19,075 | 23,009 | 18,819 |
| Operating Income (Loss) | (19,462) | (20,334) | (10,327) | (10,221) | (18,218) | (19,075) | (23,009) | (18,819) |
| Interest Income | 960.00 | 388.00 | 247.00 | 321.00 | 440.00 | 655.00 | 856.00 | 963.00 |
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (19,052) | (19,869) | (10,091) | (9,866) | (17,559) | (18,657) | (21,726) | (17,768) |
| Earnings Per Share (Basic) | (0.22) | (0.50) | (0.30) | (0.30) | (0.58) | (0.62) | (0.72) | (0.59) |
| Earnings Per Share (Diluted) | (0.22) | (0.50) | (0.30) | (0.30) | (0.58) | (0.62) | (0.72) | (0.59) |
| Weighted Average Shares Outstanding (Basic) | 86,597 | 39,480 | 33,192 | 33,192 | 30,409 | 30,164 | 30,174 | 30,174 |
| Weighted Average Shares Outstanding (Diluted) | 86,597 | 39,480 | 33,192 | 33,192 | 30,409 | 30,164 | 30,174 | 30,174 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About RLMD
Relmada Therapeutics, Inc. (NASDAQ: RLMD) is a stock listed on the Nasdaq Stock Market under the ticker symbol RLMD. It last traded at $3.15 (Oct 19, 2026, 10:15 AM ET), up 1.6% on the day. That gives Relmada Therapeutics a market capitalisation of $330.7M.
Over the past 52 weeks RLMD has traded between $1.80 and $8.00.
For the quarter ended Mar 31, 2026 it reported a net loss of $19.1M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$19.1M |
| Dec 31, 2025 | — | -$19.9M |
| Sep 30, 2025 | — | -$10.1M |
| Jun 30, 2025 | — | -$9.9M |
From Relmada Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…